InDex Pharmaceuticals develops drugs that help patients suffering from immunological diseases. Our lead drug candidate cobitolimod, currently in late-stage clinical development, has a new and unique mechanism of action to treat ulcerative colitis, a serious and chronic inflammatory bowel disease (IBD). Cobitolimod therefore has the potential to meet the need for new, effective and safe treatments so that ulcerative colitis patients can return to a more normal life.
InDex also has a broad and patent-protected platform of DIMS substances (DNA-based ImmunoModulatory Sequences) in early preclinical phases. With their immunomodulatory effects they have the potential to treat several types of immunological diseases in addition to IBDs.